68Ga	Gallium-68
AE	Adverse Event
BRCA1	Breast Cancer Gene 1
BRCA2	Breast Cancer Gene 2
CA19-9	Carbohydrate Antigen 19-9
CAR	Chimeric Antigen Receptor
CAR-NK	Chimeric Antigen Receptor Natural Killer
CAR-T	Chimeric Antigen Receptor T cell
CD73	Cluster of Differentiation 73
CDH17	Cadherin-17
CEACAM5	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5
CIK	Cytokine-Induced Killer
ctDNA	Circulating Tumor DNA
DCR	Disease Control Rate
DLT	Dose-Limiting Toxicity
DoR	Duration of Response
EGFR	Epidermal Growth Factor Receptor
ESMO	European Society for Medical Oncology
FAK	Focal Adhesion Kinase
FGFR	Fibroblast Growth Factor Receptor
FOLFIRINOX	Leucovorin, Fluorouracil, Irinotecan and Oxaliplatin
GDF-15	Growth Differentiation Factor 15
HRD	Homologous Recombination Deficiency
ICI	Immune Checkpoint Inhibitor
IMRT	Intensity-Modulated Radiation Therapy
IRE	Irreversible Electroporation
KRAS	Kirsten Rat Sarcoma Viral Oncogene Homolog
MAPK	Mitogen-Activated Protein Kinase
MAT2A	Methionine Adenosyltransferase 2A
mFOLFIRINOX	Modified FOLFIRINOX
MRI	Magnetic Resonance Imaging
MSI-H	Microsatellite Instability-High
MTAP	Methylthioadenosine Phosphorylase
MTD	Maximum Tolerated Dose
mRNA	Messenger RNA
NALIRIFOX	Liposomal Irinotecan, Fluorouracil, Leucovorin and Oxaliplatin
NCCN	National Comprehensive Cancer Network
NIH	National Institutes of Health
ORR	Objective Response Rate
OS	Overall Survival
PALB2	Partner and Localizer of BRCA2
PARP	Poly(ADP-ribose) Polymerase
PD-1	Programmed Cell Death Protein 1
PDAC	Pancreatic Ductal Adenocarcinoma
PET	Positron Emission Tomography
PFS	Progression-Free Survival
PRMT5	Protein Arginine Methyltransferase 5
RP2D	Recommended Phase II Dose
SAE	Serious Adverse Event
SBRT	Stereotactic Body Radiation Therapy
siRNA	Small Interfering RNA
TCR-T	T-cell Receptor-Engineered T cell
TEAE	Treatment-Emergent Adverse Event
TGF-β2	Transforming Growth Factor Beta 2
TIL	Tumour-Infiltrating Lymphocyte
TROP2	Trophoblast Cell Surface Antigen 2
TTR	Time to Response
VEGF	Vascular Endothelial Growth Factor